References
- Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130–41
- Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–39
- Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int 2011;31:78–84
- Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009;53:598–602
- Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferon in cancer patients: a review. J Clin Oncol 1986;4:234–43
- Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350–6
- Hayasaka S, Nagaki Y, Matsumodto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998;82:323–5
- Willson RL, Ross RD, Willson LM, et al. Interferon-associated retinopathy in a young, insulin-dependent diabetic patient. Retina 2000;20:413–15
- Schulman L, Kooragayala K. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003;110:437–42
- Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007;48:368–75
- Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041–4
- Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis C. Br J Ophthalmol 1994;78:238
- Wall M, Neahring RK, Woodward KR. Sensitivity and specificity of frequency doubling perimetry in neuro-ophthalmic disorders: a comparison with conventional automated perimetry. Invest Ophthalmol Vis Sci 2002;43:1277–83
- Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994;21:474–7
- Ikebe T, Nakatsuka K, Goto M. A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn 1190;41:2291–6
- Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004;88:1518–20
- d’Alteroche L, Majzoub S, Lecuyer AI, et al. Ophthalmic side effects during alfa-interferon therapy for viral hepatitis. J Hepatol 2006;44:56–61
- Berg KT, Nelson B, Harrison AR, et al. Peyglated interferon alpha-associated optic neuropathy. J Neuroophthalmol 2010;30:117–22
- Van Wie AM. Hepatitis C and interferon-associated retinopathy: a case report. Optometry 2011;82:739–43
- Oishi A, Miyamoto K, Kashii S, Yoshimura N. Abducens palsy and Sjögren’ syndrome induced by pegylated interferon therapy. Br J Ophthalmol 2007;91:843–4